▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2000 by analyst upside · 2026-09-27
ASND
Ascendis Pharma A/S
Healthcare · Market Cap $15B · P/E 17.7x
ANALYST PRICE TARGET
+37.5%
implied upside to consensus target
Current Price $225.6
Consensus Target $310.3
Bull Target $355.77
Bear Target $266.64
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
15
Hold
0
Sell
0
52-Week Low $186.05
52-Week High $282.15
YTD Return +5.8%
FUNDAMENTALS
Market Cap $15B
P/E Ratio (TTM) 17.7x
Forward P/E 20.6x
EPS (TTM) $12.72
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.0B
Profit Margin 70.8%
52-WEEK RANGE
52-Week Low $186.05
52-Week High $282.15
Current Price $225.6
Bear Target $266.64
Bull Target $355.77
● Now $225.6 ● Target $310.3
TRADING DATA
Avg Volume 641K
YTD Return +5.8%
Analyst Count 20
Consensus Buy
Upside to Target +37.5%
Last Updated 2026-09-27

ANALYST SUMMARY

Ascendis Pharma A/S (ASND) is currently trading at $225.6 with a Wall Street consensus price target of $310.3, implying potential upside of 37.5% over the next 12 months. 20 analysts currently cover ASND, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $355.77, while the most cautious has a target of $266.64.

ASND operates in the Healthcare sector with a market capitalisation of $15B. The stock is up 5.8% year-to-date and is currently trading near the lower end of its 52-week range of $186.05 – $282.15.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ASND, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Raymond James ↓ Downgrade
Strong Buy → Outperform 2026-09-15 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-09-02 14% win rate (7 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-01 Building track record
Wedbush reit
Outperform → Outperform 2026-09-01 Building track record
B of A Securities - Reiterated
Buy → Buy 2026-08-31 Building track record
Jefferies - Reiterated
Buy → Buy 2026-08-31 50% win rate (6 calls)
Stifel - Reiterated
Buy → Buy 2026-08-31 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-31 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
72
out of 100
Coverage depth
23/30
Consensus clarity
22/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →